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Objectives: To identify and review methods employed to evaluate medication 
adherence in studies of oral antineoplastic agents, with particular interest in the 
opportunities and challenges associated with medication event monitoring systems 
(MEMS) implemented in observational studies. MethOds: A targeted literature 
review was conducted to identify studies that have measured adherence with anti-
neoplastic agents. Our review included studies that were published between January 
1990 and May 2014. Key data abstracted from each study included patient charac-
teristics, study design and duration, cancer type, treatment, and adherence meth-
odology and results. Based on preliminary results, a second targeted review was 
conducted to evaluate the literature on the risk of the Hawthorne effect in obser-
vational studies utilizing MEMS in any therapeutic area. Results: We identified 69 
studies that evaluated adherence to oral chemotherapy; 6 studies were interven-
tional and excluded from further review. Of the remaining 63 studies, 28 (44%) were 
prospective, 25 (40%) were retrospective, and 10 (16%) were cross-sectional. A total 
of 15 studies used MEMS to evaluate medication adherence. Among observational 
studies that utilized MEMS and evaluated the Hawthorne effect (n= 3), mixed results 
were observed. In two studies, patients reported their behavior was affected by their 
awareness of being evaluated. This was demonstrated by a significant decrease in 
adherence between months 1-3 in one study but not measured in the second. The 
third study showed no change in adherence scores over time and concluded there 
was no Hawthorne effect. Potential ways to minimize the Hawthorne effect include: 
study duration > 3 months, blinding patients and physicians to results of MEMS 
downloads, and use of a patient-completed ‘debriefing form’ to assess behavior 
modifications. cOnclusiOns: MEMS have been utilized in observational studies 
evaluating oral antineoplastic agents. The Hawthorne effect may be present with 
MEMS caps, but can be minimized and is not prohibitive to study conduct.
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Objectives: Identifying appropriate utility values to inform cost-effectiveness 
analysis is a common problem. The aim of this study was to review health-state 
utility values (HSUVs) for patients with advanced ovarian cancer and make recom-
mendations about their use in the economic evaluation of a targeted maintenance 
therapy for platinum-sensitive recurrent (PSR) ovarian cancer. MethOds: A sys-
tematic search of Embase®, MEDLINE®, and MEDLINE®in Process was conducted 
in June 2013 for studies reporting direct (standard gamble (SG) or time trade off 
(TTO)) or indirect (EQ-5D, SF-6D, or HUI-3) utility values for patients with advanced 
ovarian cancer. HTA agency websites were also searched. Study design, country, 
HSUV elicitation method, health state (HS) description, and who valued the HS were 
extracted. Mean (SD) utility scores, or medians (ranges), if means were unavailable, 
were recorded for each HS. Results: A total of 10 publications were found, rep-
resenting five primary sources of utility values. Two were derived from trial-based 
patient-reported EQ-5D profiles; one derived profiles from patients with ovarian 
cancer and utility values from a sample of the general population using a SG; two 
derived HSUVs from a sample of women without cancer using a TTO. These studies 
reported utilities for 18 different health states. Where comparisons were possible, 
utility values differed widely: clinical remission 0.83-0.977; progression-free after 
recurrence 0.50-0.715; progressive disease 0.40-0.725. None of the studies reported 
values for patients receiving maintenance therapy. cOnclusiOns: There is limited 
health-state utility data for advanced ovarian cancer and wide variations in sam-
ple size, methods of elicitation, populations used to provide utility values, and in 
health state descriptions. Further research is required to provide robust estimates 
to populate an economic model for a targeted maintenance therapy for PSR ovarian 
cancer. Given the limitations of the current evidence base additional methods, such 
as mapping algorithms should be considered.
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Objectives: In cost–effectiveness analyses (CEA), a paucity of health-related qual-
ity of life (HRQoL) data often necessitates use of utility values from populations 
which may be ill-matched with the disease modelled. Use of the most pertinent data 
increases model precision and the accuracy of CEA. This systematic literature review 
aimed to identify utility values derived from the EQ-5D in patients with breast 
cancer (BC) or prostate cancer (PC). MethOds: A systematic search was conducted 
using Medline, Embase and Cochrane databases. Eligible studies for inclusion com-
prised those reporting EQ-5D utility values in patients with BC or PC at any stage, 
undergoing or not receiving treatment. Results: 31 studies reported relevant data 
(BC, 17; PC, 14). Utility values for metastatic BC (6 studies) ranged from 0.55–0.75 
and were lower for patients receiving palliative chemotherapy (CT) or terminal care 
(0.51–60), while for stage 0–III disease (9 studies), values ranged from 0.74–0.88. In 
early-stage BC there was little change during follow-up; for stage II/III BC, rapid 
and sustained recovery was observed following high-dose (HD) CT and was main-
tained long-term post-HDCT and following adjuvant CT. Values for metastatic PC (9 
studies) ranged from 0.63–0.85 and were lower for patients with bone metastases, 
worse performance status or undergoing palliative care. For localised PC (2 studies), 
Objectives: Skeletal-related events (SREs) defined as pathologic fracture, radiation 
to bone, surgery to bone and spinal cord compression, are common consequences 
of bone metastasis. Prior studies have shown that SREs increase the utilization of 
health care resources, including hospitalizations. We estimated the decrease in hos-
pitalizations when a novel superior therapy is used (denosumab), in substitution 
of zoledronic acid (zol), to treat patients with bone metastases secondary to breast 
cancer in Germany. MethOds: An analysis was run for predicting the number of SREs 
avoided and the reduction in number of hospitalizations attributable to treatment 
with denosumab. The number of breast cancer patients was collected from a German 
registry using the International Classification of Disease codes. Epidemiological data 
were then utilized to derive the number of hospitalizations due to bone metasta-
ses. The number of patients treated for SREs prevention was obtained from market 
research and applied to either treatment. The total number of SREs observed was 
based in the SREs rates seen in a phase 3 clinical trial. German data from a multina-
tional retrospective chart review was used to quantify the inpatient hospitalization 
rates and length of stay associated with each type of SRE. Results: Approximately 
9,500 patients per year with breast cancer and bone metastases were estimated to 
be treated with denosumab or zol in Germany. The resulting 2,100 SREs prevented 
per year led to a reduction of approximately 700 hospitalizations per year. The total 
number of days per inpatient stay avoided by using denosumab instead of zol was 
approximately 5,000 per year. cOnclusiOns: The superior efficacy of denosumab 
compared to zol reduces the disease burden by decreasing the number of SREs and 
consequently the number of hospitalizations and inpatient days.
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Objectives: Beyond understanding the pure cost of genomic sequencing, the 
real costs associated with implementing next-generation sequencing (NGS) into 
clinical practice are currently unknown. To elucidate the real costs and to pro-
vide a potential benchmark for reimbursement, a pilot study was conducted to 
identify and valuate the resources related to conducting clinical cancer whole-
exome (cWES), transcriptome, and targeted panel sequencing in a cohort of 
pediatric cancer patients. MethOds: A cost model was calculated using 25 pedi-
atric cancer patients who underwent clinical genomic sequencing at Columbia 
University Medical Center. Our institutional workflow developed by the Precision 
in Pediatric Sequencing (PIPseq) Program in the Division of Pediatric Oncology and 
the Personalized Genomics Medicine Laboratory in the Department of Pathology 
guided the identification of resources and costs associated with NGS. Results: 
17 pediatric patients received cWES testing and 11 patients received transcrip-
tome testing using Illumina HiSeq 2500 technology. 7 patients received targeted 
cancer panel testing using Illumina MiSeq technology. The total cost per case per 
test [cWES (tumor/normal), $4,459; transcriptome (tumor), $1,764; targeted panel 
(tumor), $383) was calculated from summing the total variable cost (reagent cost, 
pathologist time) with the fixed cost per case (annual machine cost, annual main-
tenance, tech labor cost, informatics cost, space for NGS hardware, server time, 
NGS analysis lease, and data storage). Clinical utility was demonstrated by iden-
tifying a potentially actionable mutation in 24% of participants. cOnclusiOns: 
Since the reimbursement landscape for clinical genomic sequencing is currently 
unknown, a comprehensive cost calculation reflecting resource utilization across 
the whole sequencing workflow including costs associated with directed therapy 
based on molecular profiling results is necessary. These data serve as a starting 
point toward identifying and valuating resources associated with NGS and serve 
as a first step toward demystifying reimbursement for clinical genomic sequenc-
ing in Pediatric Oncology.
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Objectives: With the start of AMNOG in 2011, industry is demanded to submit 
and defend evidence as well as negotiate discounts for new drugs with an addi-
tional patient benefit in Germany. The National Association of Statutory Health 
Insurances (SpiBu) negotiates with a discount on the ex-factory price on top of 
a mandatory discount. Evaluating final prices, questions arise regarding factors 
might influence discounts and impact the German market especially for oncologic 
and orphan drugs. MethOds: A database containing detailed information for 
all past assessments was used to explore potential impact factors for discounts. 
Starting with an analysis of background information (discount, areas etc.) descrip-
tive statistics were employed. Furthermore, we analyzed past assessments with 
respect to: number and size of target population, results of the benefit assessment, 
change in ex-factory price, magnitude of discount, incorporation of quality of life 
evidence, and acceptance of comparator therapy among others. Results: Until 
June 2014 24 price negotiations were completed for oncologic and/or orphan drugs 
(neoplasm: 16, orphan drugs [w/o oncologics]: 8). It is inconclusive, if the scale of 
benefit influences the price discount. An additional benefit was granted by the 
G-BA in 21 of 24 cases. The magnitude of the discount tends to be higher in groups 
with smaller target populations and quality of life evidence has no influence on 
the negotiated discount. Discount rates might be smaller if the companies do 
not deviate from recommendations given by the G-BA. In addition to discounts, 
some companies needed to lower their ex-factory price. cOnclusiOns: Whereas 
binding and strict rules are in place for the benefit assessment itself, there is 
no algorithm for prediction of levels of price discounts. To decrease uncertainty 
for scenario planning a set algorithm or procedure would be preferable. Further 
research is needed to evaluate those criteria.
